The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Richard W Grady - One of the best experts on this subject based on the ideXlab platform.
-
the evolution of vesicoureteral Reflux management in the era of dextranomer hyaluronic acid copolymer a pediatric health information system database study
The Journal of Urology, 2006Co-Authors: Thomas S Lendvay, Charles A Cowan, Michael M Mitchell, Byron D Joyner, Mathew D Sorensen, Richard W GradyAbstract:Purpose: Since Food and Drug Administration approval of Deflux®, injection therapy for vesicoureteral Reflux has increased. Little data exist on the effect that injection therapy has had on the incidence of ureteral reimplantation and total vesicoureteral Reflux procedures. We used the Pediatric Health Information System database to define practice trends for vesicoureteral Reflux therapy.Materials and Methods: From 2002 to 2004 we extracted data on 0 to 19-year-old patients with International Classification of Diseases-9 diagnosis codes for vesicoureteral Reflux, and procedure codes for ureteral reimplantation and subureteral injection therapy. Of 37 hospitals enrolled in Pediatric Health Information System 18 submitted ambulatory surgery and inpatient data. Data on the total number of patients who underwent reimplantation and injection were analyzed using linear regression analysis for trend.Results: We identified a total of 4,570 procedures performed in 1,948 patients treated with injection therapy and...
-
the evolution of vesicoureteral Reflux management in the era of dextranomer hyaluronic acid copolymer a pediatric health information system database study
The Journal of Urology, 2006Co-Authors: Thomas S Lendvay, Charles A Cowan, Michael M Mitchell, Byron D Joyner, Mathew D Sorensen, Richard W GradyAbstract:Purpose: Since Food and Drug Administration approval of Deflux®, injection therapy for vesicoureteral Reflux has increased. Little data exist on the effect that injection therapy has had on the inc...
Eric Colhoun - One of the best experts on this subject based on the ideXlab platform.
-
subureteral dextranomer hyaluronic acid injection as first line treatment in the management of high grade vesicoureteral Reflux
The Journal of Urology, 2006Co-Authors: Prem Puri, Nochiparambil Mohanan, Martina A Pirker, Michal Dawrant, Laxman Dass, Eric ColhounAbstract:Purpose: Endoscopic correction of vesicoureteral Reflux has become an established alternative to long-term antibiotic prophylaxis and ureteral reimplantation. A number of tissue augmenting substances have been used for the endoscopic correction of vesicoureteral Reflux. We prospectively evaluated the effectiveness of dextranomer/hyaluronic acid copolymer (Deflux®) as first line treatment for high grade vesicoureteral Reflux.Materials and Methods: Between 2001 and 2004, 692 children with a median age of 2.1 years (3 months to 13.7 years) with high grade vesicoureteral Reflux underwent endoscopic subureteral injection of Deflux® soon after the diagnosis of vesicoureteral Reflux was made on the initial voiding cystourethrogram. Vesicoureteral Reflux was unilateral in 283 patients and bilateral in 409. Of the 1,101 ureters vesicoureteral Reflux was grade II to V in 35 (3.2%), 580 (52.7%), 457 (41.5%) and 29 (2.6%), respectively. The procedure was performed on an outpatient basis. Followup ultrasound and voidi...
-
treatment of vesicoureteral Reflux by endoscopic injection of dextranomer hyaluronic acid copolymer preliminary results
The Journal of Urology, 2003Co-Authors: Prem Puri, Boris Chertin, Murugesh Velayudham, Laxaman Dass, Eric ColhounAbstract:ABSTRACTPurpose: Endoscopic subureteral injection of tissue augmenting substances has become an established alternative to long-term antibiotic prophylaxis and open surgery for the management of vesicoureteral Reflux (VUR) in children. Recently, dextranomer/hyaluronic acid copolymer (Deflux, Q-Med AB, Uppsala, Sweden) a biodegradable injectable material has been reported to be a promising alternative to other tissue augmenting substances. However, the experience with dextranomer/hyaluronic acid copolymer is limited. We prospectively evaluate the effectiveness of dextranomer/hyaluronic acid copolymer in the endoscopic treatment of VUR.Materials and Methods: A total of 32 males and 81 females with a median age of 1 year (range 3 months to 10 years) underwent endoscopic correction of primary VUR with dextranomer/hyaluronic acid copolymer. Reflux was unilateral in 58 cases and bilateral in 54, affecting 166 ureters. Reflux was grades II to V in 7 (4.2%) cases, 91 (54.8%), 63 (38%) and 5 (3%), respectively. Al...
Thomas S Lendvay - One of the best experts on this subject based on the ideXlab platform.
-
injection volumes of dextranomer hyaluronic acid are increasing in the endoscopic management of vesicoureteral Reflux
Pediatric Surgery International, 2010Co-Authors: Mathew D Sorensen, Charles A Cowan, Ismael Zamilpa, Martin A. Koyle, Margarett Shnorhavorian, Thomas S LendvayAbstract:Purpose Dextranomer/hyaluronic acid (Deflux®) has been increasingly used for the treatment of vesicoureteral Reflux (VUR). Experience has shown that injecting more volume of material is necessary to achieve greater success. We evaluate trends in the number of vials being used to treat VUR using a multi-institutional database and data from patients treated at our own institution.
-
the evolution of vesicoureteral Reflux management in the era of dextranomer hyaluronic acid copolymer a pediatric health information system database study
The Journal of Urology, 2006Co-Authors: Thomas S Lendvay, Charles A Cowan, Michael M Mitchell, Byron D Joyner, Mathew D Sorensen, Richard W GradyAbstract:Purpose: Since Food and Drug Administration approval of Deflux®, injection therapy for vesicoureteral Reflux has increased. Little data exist on the effect that injection therapy has had on the incidence of ureteral reimplantation and total vesicoureteral Reflux procedures. We used the Pediatric Health Information System database to define practice trends for vesicoureteral Reflux therapy.Materials and Methods: From 2002 to 2004 we extracted data on 0 to 19-year-old patients with International Classification of Diseases-9 diagnosis codes for vesicoureteral Reflux, and procedure codes for ureteral reimplantation and subureteral injection therapy. Of 37 hospitals enrolled in Pediatric Health Information System 18 submitted ambulatory surgery and inpatient data. Data on the total number of patients who underwent reimplantation and injection were analyzed using linear regression analysis for trend.Results: We identified a total of 4,570 procedures performed in 1,948 patients treated with injection therapy and...
-
the evolution of vesicoureteral Reflux management in the era of dextranomer hyaluronic acid copolymer a pediatric health information system database study
The Journal of Urology, 2006Co-Authors: Thomas S Lendvay, Charles A Cowan, Michael M Mitchell, Byron D Joyner, Mathew D Sorensen, Richard W GradyAbstract:Purpose: Since Food and Drug Administration approval of Deflux®, injection therapy for vesicoureteral Reflux has increased. Little data exist on the effect that injection therapy has had on the inc...
Prem Puri - One of the best experts on this subject based on the ideXlab platform.
-
subureteral dextranomer hyaluronic acid injection as first line treatment in the management of high grade vesicoureteral Reflux
The Journal of Urology, 2006Co-Authors: Prem Puri, Nochiparambil Mohanan, Martina A Pirker, Michal Dawrant, Laxman Dass, Eric ColhounAbstract:Purpose: Endoscopic correction of vesicoureteral Reflux has become an established alternative to long-term antibiotic prophylaxis and ureteral reimplantation. A number of tissue augmenting substances have been used for the endoscopic correction of vesicoureteral Reflux. We prospectively evaluated the effectiveness of dextranomer/hyaluronic acid copolymer (Deflux®) as first line treatment for high grade vesicoureteral Reflux.Materials and Methods: Between 2001 and 2004, 692 children with a median age of 2.1 years (3 months to 13.7 years) with high grade vesicoureteral Reflux underwent endoscopic subureteral injection of Deflux® soon after the diagnosis of vesicoureteral Reflux was made on the initial voiding cystourethrogram. Vesicoureteral Reflux was unilateral in 283 patients and bilateral in 409. Of the 1,101 ureters vesicoureteral Reflux was grade II to V in 35 (3.2%), 580 (52.7%), 457 (41.5%) and 29 (2.6%), respectively. The procedure was performed on an outpatient basis. Followup ultrasound and voidi...
-
treatment of vesicoureteral Reflux by endoscopic injection of dextranomer hyaluronic acid copolymer preliminary results
The Journal of Urology, 2003Co-Authors: Prem Puri, Boris Chertin, Murugesh Velayudham, Laxaman Dass, Eric ColhounAbstract:ABSTRACTPurpose: Endoscopic subureteral injection of tissue augmenting substances has become an established alternative to long-term antibiotic prophylaxis and open surgery for the management of vesicoureteral Reflux (VUR) in children. Recently, dextranomer/hyaluronic acid copolymer (Deflux, Q-Med AB, Uppsala, Sweden) a biodegradable injectable material has been reported to be a promising alternative to other tissue augmenting substances. However, the experience with dextranomer/hyaluronic acid copolymer is limited. We prospectively evaluate the effectiveness of dextranomer/hyaluronic acid copolymer in the endoscopic treatment of VUR.Materials and Methods: A total of 32 males and 81 females with a median age of 1 year (range 3 months to 10 years) underwent endoscopic correction of primary VUR with dextranomer/hyaluronic acid copolymer. Reflux was unilateral in 58 cases and bilateral in 54, affecting 166 ureters. Reflux was grades II to V in 7 (4.2%) cases, 91 (54.8%), 63 (38%) and 5 (3%), respectively. Al...
Mathew D Sorensen - One of the best experts on this subject based on the ideXlab platform.
-
injection volumes of dextranomer hyaluronic acid are increasing in the endoscopic management of vesicoureteral Reflux
Pediatric Surgery International, 2010Co-Authors: Mathew D Sorensen, Charles A Cowan, Ismael Zamilpa, Martin A. Koyle, Margarett Shnorhavorian, Thomas S LendvayAbstract:Purpose Dextranomer/hyaluronic acid (Deflux®) has been increasingly used for the treatment of vesicoureteral Reflux (VUR). Experience has shown that injecting more volume of material is necessary to achieve greater success. We evaluate trends in the number of vials being used to treat VUR using a multi-institutional database and data from patients treated at our own institution.
-
the evolution of vesicoureteral Reflux management in the era of dextranomer hyaluronic acid copolymer a pediatric health information system database study
The Journal of Urology, 2006Co-Authors: Thomas S Lendvay, Charles A Cowan, Michael M Mitchell, Byron D Joyner, Mathew D Sorensen, Richard W GradyAbstract:Purpose: Since Food and Drug Administration approval of Deflux®, injection therapy for vesicoureteral Reflux has increased. Little data exist on the effect that injection therapy has had on the incidence of ureteral reimplantation and total vesicoureteral Reflux procedures. We used the Pediatric Health Information System database to define practice trends for vesicoureteral Reflux therapy.Materials and Methods: From 2002 to 2004 we extracted data on 0 to 19-year-old patients with International Classification of Diseases-9 diagnosis codes for vesicoureteral Reflux, and procedure codes for ureteral reimplantation and subureteral injection therapy. Of 37 hospitals enrolled in Pediatric Health Information System 18 submitted ambulatory surgery and inpatient data. Data on the total number of patients who underwent reimplantation and injection were analyzed using linear regression analysis for trend.Results: We identified a total of 4,570 procedures performed in 1,948 patients treated with injection therapy and...
-
the evolution of vesicoureteral Reflux management in the era of dextranomer hyaluronic acid copolymer a pediatric health information system database study
The Journal of Urology, 2006Co-Authors: Thomas S Lendvay, Charles A Cowan, Michael M Mitchell, Byron D Joyner, Mathew D Sorensen, Richard W GradyAbstract:Purpose: Since Food and Drug Administration approval of Deflux®, injection therapy for vesicoureteral Reflux has increased. Little data exist on the effect that injection therapy has had on the inc...
